Root Financial Partners
CRSP icon

Root Financial Partners’s CRISPR Therapeutics CRSP Stock Holding History

Root Financial Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.77K Buy
+32
New +$1.73K ﹤0.01% 2702
2026
Q2 		– Sell
-15
Closed -$714 – 1026
2026
Q1 		$714 Sell
15
-17
-53% -$897 ﹤0.01% 2739
2025
Q4 		$1.68K Buy
+32
New +$1.92K ﹤0.01% 2016

Other funds holding CRSP

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Root Financial Partners's CRSP Position: Q3 2026 in Review

Root Financial Partners opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 32 shares worth $1.77K. The stake represents ﹤0.01% of the portfolio and ranks #2702 among its holdings. This is a return to the name: Root Financial Partners previously reported a position in CRSP as recently as Q1 2026.

Root Financial Partners first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 340 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Root Financial Partners held 32 shares of CRISPR Therapeutics worth $1.77K as of Q3 2026.
  • CRISPR Therapeutics was a new Root Financial Partners position in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #2702 holding.
  • Root Financial Partners first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 340 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.